(INNF)
TELISOTUZUMAB(INNS)
TELISOTUZUMAB(SLE)
TELISOTUZUMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS MET (MET PROTO-ONCOGENE, HEPATOCYTE GROWTH FACTOR (HGF) RECEPTOR, HGFR, SCATTER FACTOR (SF) RECEPTOR, HGF/SF RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE C-MET, PAPILLARY RENAL CELL CARCINOMA 2, RCCP2)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-445) [HUMANIZED VH (HOMO SAPIENS IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -HOMO SAPIENS IGHG1*03, G1M3 (CH1 (119-216), HINGE K7>DEL, T8>C (223), T10>DEL (217-229), CH2 (230- 339), CH3 (340-444), CHS K>DEL (445)) (119-445)], (221- 218')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-218') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV4-1*01 (85.10%) - IGKJ4*01) [10.3.9] (1'-111') -HOMO SAPIENS IGKC*01, KM3 (112'-218')]; DIMER (223-223":225-225":228:228")- TRISDISULFIDE, RECOMMENDED INN: LIST 77(WHO)
TELISOTUZUMABUM(INN)